Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin.
As assessed by urine pyridinium cross-links, bone resorption increases at night. This has been ascribed to either the nocturnal rise of serum parathyroid hormone (PTH) or immobilization. ICTP is the carboxyterminal telopeptide region of type I collagen in bone, cross-linked via pyridinium cross-links and liberated during the degradation of type I collagen. To study whether the nocturnal rise in bone resorption is seen also in serum type I collagen carboxyterminal telopeptide (ICTP) and whether this rise is abolished by bedtime calcium or calcitonin, nine healthy postmenopausal women participated in three 24 hour sessions. At 2200 hours, either 1 g of oral calcium or 200 IU of intranasal calcitonin or no treatment (control session) were given. The participants were recumbent from 2200 hours to 0600 hours. Like urinary pyridinolines, serum ICTP showed a clearcut nocturnal rise during the control session, increasing from 3.7 +/- 0.3 micrograms/liter (mean +/- SE) at 2000 hours to 4.9 +/- 0.4 micrograms/liter at 0600 hours (P < 0.001). Administration of calcium did not affect either serum ICTP or urinary pyridinolines, although it decreased serum intact PTH by 18% (P < 0.001) as assessed by areas under curve (AUC) after 2200 hours. Serum ICTP and urinary pyridinolines remained unchanged also after administration of calcitonin which increased the AUC for serum intact PTH by 9% (P < 0.05). In conclusion, serum ICTP follows a circadian rhythm in healthy postmenopausal women. The nocturnal rise in markers of bone resorption is not due to PTH, and its dependency on the function of osteoclasts is open to question.
Sairanen
S
S
Third Department of Medicine, Helsinki University Central Hospital, Finland.
Tähtelä
R
R
Laitinen
K
K
Karonen
S L
SL
Välimäki
M J
MJ
D000281:Administration, Intranasal; D000284:Administration, Oral; D000368:Aged; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000188:drug therapy*; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D002940:Circadian Rhythm; D003094:Collagen / Q000097:blood* / Q000652:urine; D024042:Collagen Type I; D003432:Cross-Linking Reagents; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy / Q000652:urine; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood* / Q000652:urine; D011863:Radioimmunoassay; D012890:Sleep
D000596:Amino Acids; D015415:Biomarkers; D024042:Collagen Type I; D003432:Cross-Linking Reagents; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; C015484:pyridinoline; D002116:Calcitonin; D003094:Collagen; D002118:Calcium